Volver a Agenda
Session Chair(s)
Noriaki Murao, DIAFellow, MS
Senior Consultant (Pharmaceuticals)
NM Consulting, Japan
Learning Objective : Discuss an overview of the development of orphan drug strategies in large and small pharmaceutical companies; Describe considerations on planning and commercialization strategies of orphan drugs.
Speaker(s)
Perspective on Orphan Drug Development: From the Industry Viewpoint
Yoshihiko Ono, RPH
MSD K.K., Japan
Regulatory Executive Advisor
Evolution of a Biotech from Startup to Mid Cap: Making the Orphan Disease Strategy Happen
Kenneth N. Hitchner, MA
BioMarin Pharmaceutical Inc., United States
Vice President, Development Sciences Project Management
Value and Specificity of Rare Diseases Business Model: Is the Pursuit of This Societal Priority Sustainable?
Michael C. Diem, MD
GlaxoSmithKline, United States
Director and Head of Business Development, GSK Rare Diseases
¿Tiene una cuenta?